ArticleNeuroscience letters2017
Cognitive ability in Down syndrome and its relationship to urinary neopterin, a marker of activated cellular immunity.
Article in Neuroscience letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 18 citations in OpenAlex.
- Exploring peripheral fluid biomarkers for early detection of Alzheimer's disease in Down syndrome: A literature review.Heliyon · 2025Review
- Evidence of neuroinflammation and immunotherapy responsiveness in individuals with down syndrome regression disorder.Journal of neurodevelopmental disorders · 2022Article
- The Clinical and Neuropathological Features of Sporadic (Late-Onset) and Genetic Forms of Alzheimer's Disease.Journal of clinical medicine · 2021Review
- Opportunities, barriers, and recommendations in down syndrome research.Translational science of rare diseases · 2021Article
- Acute Effects of Triathlon Race on Oxidative Stress Biomarkers.Oxidative medicine and cellular longevity · 2020Article
- Integrative Analysis Extracts a Core ceRNA Network of the Fetal Hippocampus With Down Syndrome.Frontiers in genetics · 2020Article
- Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease.Alzheimer's research & therapy · 2019Article
- Increased Oxidative Stress as a Risk Factor in Chronic Idiopathic Axonal Polyneuropathy.Journal of molecular neuroscience : MN · 2018Article
- Neurofilament light as a blood biomarker for neurodegeneration in Down syndrome.Alzheimer's research & therapy · 2018Article
- Tau-Induced Pathology in Epilepsy and Dementia: Notions from Patients and Animal Models.International journal of molecular sciences · 2018Review
- Clinical aspects and biomarkers of Alzheimer's disease in Down syndrome.Free radical biology & medicine · 2018Review
- Antishock Characteristics of Erythrocyte-mediated Endoplasmic Reticulum Stress in Macrophages in Severe Hemorrhagic Shock Environment Based on TLR9-cGAS-STING-IFN Signal Axis.Cell transplantationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundNeopterin is an unconjugated pteridine that is secreted in large quantities by activated macrophages and can be used as a clinical marker of activated cellular immunity and oxidative stress. We aimed to investigate whether urinary neopterin levels are associated with cognitive function in people with Down syndrome (DS).
methodsOut of 32 adults with DS who originally participated in a longitudinal study, 25 were followed up at 4 years. Informants rated their adaptive behavior (ABAS) and the adults with DS attempted assessments of language skills and memory at both baseline and follow-up time points (Modified Memory Object Task, MOMT), and receptive vocabulary (British Picture Vocabulary Scale, BPVS).
resultsNeopterin/creatinine levels were negatively correlated with change in the MOMT total score (Spearman's Rho=-0.517, p=0.020) and change in the MOMT delayed recall score (Spearman's Rho=-0.577, p=0.008) over time, i.e. higher neopterin/creatinine level was associated with worse performance on a test of cognitive ability over time.
conclusionUrine neopterin may have potential as a biomarker for memory decline in Down syndrome, and could potentially also help to track progression of mild cognitive impairment (MCI) to Alzheimer's disease in other high risk populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.